Shares of Hims & Hers Health Inc. (HIMS) surged 5.31% on Thursday, outperforming the broader market during the intraday trading session. The telehealth company's stock rallied amidst attention and buzz surrounding its provocative Super Bowl commercial criticizing weight-loss drug makers and the U.S. healthcare system.

While the controversial ad has prompted backlash from Senators Richard Durbin and Roger Marshall, who have requested an FDA investigation into potential misleading claims, it has also generated significant publicity for the company. Despite the controversy, Hims & Hers remains a highly rated stock in its industry group, with strong rankings for its Composite Rating, EPS Rating, and Relative Strength Rating.

Investors appear to be anticipating positive news from the company's upcoming earnings report scheduled for February 24th, which could provide further insight into its performance and outlook. The stock's rally highlights the market's interest in Hims & Hers and its ability to capitalize on the attention generated by its bold marketing strategy.